30岁及以下乳腺癌术后首次复发转移特点分析

来源期刊：广州医药 | 50-54 发布时间：2021-11-28 收稿时间：2025/11/13 17:57:49 阅读量：16

作者：: 李亮,

张锦丰,

吴静娜,

王秋明,

关键词：: 青年乳腺恶性肿瘤肿瘤转移; Young patients Breast Neoplasms Neoplasm Metastasis

DOI：: 10.3969/j.issn.1000-8535.2020.01.012

收稿时间：: 2019-07-24
修订日期：
接收日期：
引用总数：: 0

目的探讨分析30岁及以下青年乳腺癌患者术后首次复发转移特点,以期指导术后随访,早期发现转移病灶。方法回顾性分析2003年1月—2018年8月在梅州市人民医院收治的年龄≤30岁乳腺癌患者73例,所有患者均行根治性手术治疗,分析临床病理特点及术后首次复发转移特点。结果共纳入23例三阴性(31.5%)、20例luminal B(HER2-)型(27.4%)、12例HER-2阳性型(16.4%)、10例 Luminal B(HER2+)型(13.7%)、4例Luminal A型(5.5%)和4例分型不明(5.5%)。中位随访28.4个月,7例三阴性(7/23, 30.4%)、 6例HER-2阳性型(6/12, 50.0%)、 4例Luminal B(HER2-)型(4/20, 20.0%) 和3例 Luminal B(HER2+)型(3/10, 30.0%)出现复发转移。复发转移患者中,90.0%合并远处转移,75.0%合并内脏转移,其中HER-2阳性型均合并内脏转移;92.3%(12/13)激素受体阴性患者复发转移发生在术后2年内。三阴性患者最常见远处转移部位是远处淋巴结,HER-2阳性型患者最常见远处转移部位是肝,luminal B(HER2+)型患者最常见远处转移部位是肺和骨,luminal B(HER2-)型患者最常见远处转移部位是肺和远处淋巴结。结论 ≤30岁青年乳腺癌患者术后首次复发转移多合并远处转移,激素受体阴性患者容易早期复发,不同分子分型患者具有不同的好发远处转移部位。

1、李惠平,冉然,李鹍,等. 176例HER2阳性乳腺癌首发转移部位的分析[J]. 癌症进展, 2016(12):1167-1169.

2、 CADOO K A, FORNIER M, Morris PG.Biological subtypes of breast cancer: current concepts and implications for recurrence patterns[J]. Nucl Med Mol Imaging, 2013,57(4):312-321.

3、 SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med,2018,379(22):2108-2121.

4、 BECA F, SANTOS R, VIEIRA D, et al. Primary relapse site pattern in women with triple-negative breast cancer[J]. Pathol Res Pract,2014,210(9):571-575.

5、李惠平,刘笑然,孔维垚,等. 125例三阴性复发转移乳腺癌首发转移模式的分析[J]. 癌症进展, 2016(12):1184-1186.

6、 KAST K, LINK T, FRIEDRICH K, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome[J]. Breast Cancer Res Treat,2015,150(3):621-629.

7、 CAMERON D,PICCART GEBHART M J, GELBER R D,et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial[J]. Lancet,2017,389(10075): 1195-1205.

8、 FIGUEROA MAGALHAES M C,JELOVAC D,CONNOLLY R,et al. Treatment of HER2-positive breast cancer[J]. Breast,2014,23(2):128-136.

9、 SAMUEL C A, PINHEIRO L C, Reeder-Hayes KE, et al. To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors[J]. Breast Cancer Res Treat, 2016, 160(1):1-15.

10、 COATES A S, WINER E P, GOLDHIRSCH A,et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol,2015,26(8):1533-1546.

11、 HIRONAKA-MITSUHASHI A,TSUDA H,YOSHIDA M,et al. Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years[J]. Breast Cancer, 2019,26(3): 386-396.

12、 WANG W,WANG X,LIU J,et al. Breast cancer in young women of Chinese Han population: A retrospective study of patients under 25 years[J]. Pathol Res Pract,2016, 212(11):1015-1020.

13、 DARWISH A D,HELAL A M,ALY EL-DIN N H,et al. Breast cancer in women aging 35 years old and younger: The Egyptian National Cancer Institute(NCI) experience[J]. The Breast,2017(31):1-8.

14、 RYU J M, YU J, KIM S I, et al. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res Treat,2017,166(3): 833-842.

15、 TANG L C,JIN X,YANG H Y,et al. Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China[J]. BMC Cancer,2015,15:201-207.

16、 FREDHOLM H,MAGNUSSON K,LINDSTR?M L S,et al. Long-term outcome in young women with breast cancer: a population-based study[J]. Breast Cancer Res Treat,2016, 160(1):131-143.